Last Updated Nov 7, 2026

On This Page – Quick Medical Summary

The FDA approved enlicitide, sold as Lipfendra, in July 2026, making it the first PCSK9 inhibitor that comes as a tablet instead of an injection (Fierce Pharma report on the approval). In two trials of adults who were already taking a statin, one 20 mg tablet a day lowered LDL cholesterol by 56% and 59% more than placebo after 24 weeks (Lipfendra prescribing information).

That result leaves statins in first place. The 2026 ACC/AHA dyslipidemia guideline keeps them as the starting treatment, the new pill was studied on top of one, and no trial has yet shown that it prevents heart attacks or strokes.

Where the first oral PCSK9 pill fits

An older man holding a white PCSK9 inhibitor tablet beside an injection pen at a pharmacy counter — Enlicitide blocks the same protein as the injectable antibodies evolocumab and alirocumab, but it comes as a daily pill.

The 2026 guideline sets an order: a statin at the highest dose you tolerate, then a nonstatin medicine added if LDL stays above goal (2026 ACC/AHA guideline on the management of dyslipidemia).

PCSK9 is a protein that destroys LDL receptors, the docking sites liver cells use to pull LDL out of the blood. Blocking it leaves more receptors working, so blood LDL falls. Enlicitide binds PCSK9 that is already circulating, the same target as the injectable antibodies evolocumab (Repatha) and alirocumab (Praluent). Inclisiran (Leqvio) works one step earlier, by reducing how much PCSK9 the liver makes (review of enlicitide in US Pharmacist).

Medicine	How it is taken	Typical LDL drop	Shown to cut heart attacks or strokes?
Statin, moderate intensity	Daily pill	30–49%	Yes
Statin, high intensity	Daily pill	50% or more	Yes
Ezetimibe	Daily pill	About 18% alone; about 25% added to a statin	Yes (IMPROVE-IT trial)
Bempedoic acid	Daily pill	About 21–24% in people who cannot take statins	Yes (CLEAR Outcomes trial)
Evolocumab or alirocumab	Injection under the skin	About 45–64%	Yes, in people with established heart or artery disease
Inclisiran	Injection at the start, at 3 months, then every 6 months	About 50%	Outcome trials still running
Enlicitide (Lipfendra)	Daily pill on an empty stomach	56–59% more than placebo, with a statin	Not yet known; outcome trial running

Sources: US Pharmacist for LDL ranges and nonstatin outcome evidence; MedlinePlus on statins for statin outcomes; Lipfendra label for enlicitide.

The label does not require a statin, a diagnosis of heart disease or familial hypercholesterolemia, the inherited form of very high LDL (pharmacist review of the label). The evidence behind it comes almost entirely from statin users. In CORALreef Lipids, the larger trial, 97% of 2,904 adults with heart or artery disease or a high risk of it were on a statin at the start, and every participant in the familial hypercholesterolemia trial was taking one (prescribing information).

Why do statins still come first?

Statins have the evidence patients care about most: they lower the risk of heart attack and stroke in people with high LDL (MedlinePlus).

Enlicitide was approved on its LDL results. No completed trial shows that it reduces heart attacks, strokes or deaths from heart disease; a large outcome trial, CORALreef Outcomes, is testing that, with results not expected for several years (US Pharmacist). Until then, its expected benefit is borrowed from two facts: lower LDL means fewer events, and the injectable PCSK9 antibodies, which lower LDL by a similar amount, have outcome data.

The guideline came out in March 2026, four months before the approval, so its list of add-ons covers ezetimibe, bempedoic acid, the PCSK9 antibodies and inclisiran, with nothing on enlicitide (2026 guideline). If you have not started any cholesterol medicine yet, how doctors decide whether you need a statin is the earlier question.

Before you change a medicine: Keep taking your statin unless the doctor who prescribed it tells you otherwise. Enlicitide’s approval rests on LDL drops measured in people who stayed on their statin, so starting it means adding a drug, and nothing in the approval supports swapping one for the other on your own.

55, 70 or 100 mg/dL: the LDL goal behind the decision

A phlebotomist drawing blood from a man’s inner elbow for an LDL test before PCSK9 treatment is considered — The 2026 ACC/AHA LDL goals are under 55, under 70 or under 100 mg/dL, depending on your risk.

Under 55 mg/dL is the 2026 goal for people with atherosclerotic cardiovascular disease (a past heart attack, stroke or artery blockage) who are at very high risk. Under 70 mg/dL applies to people at high risk, and under 100 mg/dL to people at borderline or intermediate risk who have not had an event (2026 guideline goals). The other changes in the 2026 cholesterol guideline include universal lipoprotein(a) testing and a new risk calculator.

A worked example shows how the goal shapes the choice.

Sample report: LDL-C 88 mg/dL, measured while taking atorvastatin 80 mg daily, in a person who had a heart attack two years ago.

The goal for that person is under 55 mg/dL, so LDL has to fall by 33 mg/dL, a cut of about 38%. Adding ezetimibe, at roughly another 25%, would bring 88 to about 66 mg/dL, still above goal. In CORALreef Lipids, LDL fell by an average of 57% in the treated group (label, Table 1); the same average would take 88 to about 38 mg/dL.

Averages describe groups, and one person’s response can land well above or below them. The arithmetic shows why a PCSK9 drug comes up for someone in this position. Whether that means the injection or the pill depends on outcome evidence, cost, coverage and whether a daily fasting routine fits your mornings. It also helps to know how your lab arrives at the LDL number on your report, since many reports calculate it rather than measure it directly.

How Lipfendra is taken each morning

The dose is one 20 mg tablet, once a day, and the label is specific about the rest (prescribing information):

Take it in the morning on an empty stomach, with water, black coffee or plain tea.
Swallow it whole; do not split, crush or chew it.
Wait at least 30 minutes before eating or drinking anything other than water, black coffee or plain tea.
If you miss a dose, take it as soon as you can while you still have 30 minutes before your next food or drink, and never take two doses in one day.

The wait has a measurable reason. Only about 1% of each dose is absorbed, helped by an ingredient called sodium caprate, and taking the tablet 30 minutes after a meal cut the amount in the blood by about half: 48% for total exposure and 50% for the peak (label, section 12.3).

Other morning medicines can go down with it. Interaction testing found no meaningful change with levothyroxine, atorvastatin, warfarin or oral semaglutide, among others, although each of those medicines keeps its own instructions (US Pharmacist). The tablets stay in their original bottle with the moisture-absorbing packet, cap closed, which rules out a weekly pill organizer.

Side effects were close to placebo in most people

Across the larger trial, side effects were about as common with enlicitide as with placebo, and similar shares of people stopped treatment because of one (prescribing information). In the familial hypercholesterolemia trial, two were more frequent: dizziness in 9% of people on enlicitide versus 4% on placebo, and diarrhea in 7% versus 2%.

There are no listed contraindications. Kidney disease, including dialysis, did not change blood levels in a meaningful way, and moderate liver disease had no effect; severe liver disease has not been studied (US Pharmacist).

Pregnancy is the main exception. The label says to stop enlicitide when pregnancy is recognized unless the benefit outweighs the possible risk to the fetus, and there is no information on whether it passes into breast milk. Its safety in children is not known (prescribing information).

Lipfendra’s list price and insurance

Merck set the list price at $315 for a 30-tablet bottle before discounts, roughly half the list price of the PCSK9 medicines already on the market (Fierce Pharma). Coverage and prior authorization may decide whether you can start and stay on it. Records of your LDL before treatment, the statins and doses you have tried, your response and any statin side effects can support a prior authorization request (US Pharmacist).

Take your on-statin LDL result to the appointment

The most useful number for this conversation is your LDL measured on the highest statin dose you tolerate. These questions cover the decision:

Which LDL goal applies to me: under 55, under 70 or under 100 mg/dL?
Am I on the highest statin dose I can tolerate, and has ezetimibe been tried?
If I need a PCSK9 drug, how does the injection, with its heart attack and stroke data, compare with the daily pill for me?
Will my plan require prior authorization, and which records should I gather first?

If you do start enlicitide, its effect on LDL can be checked as early as 4 weeks (US Pharmacist), and comparing that result with your last on-statin value shows how much it added.